Author:
Yuan JianYe,Guo Lin,Ma JiaTing,Zhang HeJian,Xiao MingXuan,Li Ning,Gong Hui,Yan Miao
Abstract
AbstractDrug-induced organic damage encompasses various intricate mechanisms, wherein HMGB1, a non-histone chromosome-binding protein, assumes a significant role as a pivotal hub gene. The regulatory functions of HMGB1 within the nucleus and extracellular milieu are interlinked. HMGB1 exerts a crucial regulatory influence on key biological processes including cell survival, inflammatory regulation, and immune response. HMGB1 can be released extracellularly from the cell during these processes, where it functions as a pro-inflammation cytokine. HMGB1 interacts with multiple cell membrane receptors, primarily Toll-like receptors (TLRs) and receptor for advanced glycation end products (RAGE), to stimulate immune cells and trigger inflammatory response. The excessive or uncontrolled HMGB1 release leads to heightened inflammatory responses and cellular demise, instigating inflammatory damage or exacerbating inflammation and cellular demise in different diseases. Therefore, a thorough review on the significance of HMGB1 in drug-induced organic damage is highly important for the advancement of pharmaceuticals, ensuring their effectiveness and safety in treating inflammation as well as immune-related diseases. In this review, we initially outline the characteristics and functions of HMGB1, emphasizing their relevance in disease pathology. Then, we comprehensively summarize the prospect of HMGB1 as a promising therapeutic target for treating drug-induced toxicity. Lastly, we discuss major challenges and propose potential avenues for advancing the development of HMGB1-based therapeutics.
Graphical Abstract
Graphical Headlights
(1) A comprehensive overview of the intricate relationship between HMGB1 and drug-induced organ toxicity is presented, accompanied by the corresponding treatment strategies.
(2) The present study addresses significant obstacles and suggests potential strategies for furthering the progress of HMGB1-based therapeutics.
(3) The research prospects of HMGB1 are also summarized.
Funder
National Natural Science Foundation of China
Science Fund for Distinguished Young Scholars of Hunan Province
Publisher
Springer Science and Business Media LLC
Reference251 articles.
1. Adachi H, Ioppolo F, Paoloni M, Santilli V. Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation. Eur Rev Med Pharmacol Sci. 2011;15(7).
2. Alabed S, Zhou H, Sariyer IK, Chang SL. Meta-Analysis of Methamphetamine Modulation on Amyloid Precursor Protein through HMGB1 in Alzheimer’s Disease. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22094781.
3. Alzokaky AA, Abdelkader EM, El-Dessouki AM, Khaleel SA, Raslan NA. C-phycocyanin protects against ethanol-induced gastric ulcers in rats: Role of HMGB1/NLRP3/NF-κB pathway. Basic Clin Pharmacol Toxicol. 2020;127:265–77. https://doi.org/10.1111/bcpt.13415.
4. Alzokaky AA, Al-Karmalawy AA, Saleh MA, Abdo W, Farage AE, Belal A, Abourehab MAS, Antar SA. Metformin ameliorates doxorubicin-induced cardiotoxicity targeting HMGB1/TLR4/NLRP3 signaling pathway in mice. Life Sci. 2023;316:121390. https://doi.org/10.1016/j.lfs.2023.121390.
5. An J, Mehrhof F, Harms C, Lättig-Tünnemann G, Lee SL, Endres M, Li M, Sellge G, Mandić AD, Trautwein C, Donath S. ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis. J Hepatol. 2013;58:297–305. https://doi.org/10.1016/j.jhep.2012.10.002.